Should You Buy This Stock After a Regulatory Setback?
The past two-and-a-half years have been rough for Moderna (NASDAQ: MRNA). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche to shrink started selling off the stock in early 2022. The vaccine maker's shares are down by 43% since then.
Moderna isn't resting on its laurels, though. The company is developing several exciting candidates. Unfortunately, the most advanced of the bunch recently ran into a regulatory setback. Let's look deeper into that recent news and what it could mean for investors.
Source Fool.com